Table 1.
Myeloid leukemia samples used in determining subcellular localization of NE and P3.
| Sample | Leukemia type |
Source | Cell Count* (K/uL) |
%Blasts* | Cytogenetic/Molecular Abnormalities | Phenotype |
|---|---|---|---|---|---|---|
| Evaluated for NE | ||||||
| Pt #1 | FAB-M1 | LP | 42 | 89 | Diploid 46XY; FLT3+ | CD13/33/38/117+; MPO+ |
| Pt #2 | FAB-M1 | LP | 86 | 86 | Diploid 46XX; FLT3+ | CD13/33/117+; HLA-DR+ |
| Pt #3 | FAB-M1 | LP | 38 | 92 | Hyperdiploid 47XY; +4; FLT3+;NPM1+ | CD13/33/34/38/117+; MPO+ |
| Pt #4 | FAB-M5 | LP | 114 | 89 | Pseudodiploid 46XY; t(6;11) | CD13/14/33/64+; HLA-DR+; MPO+ |
| Pt #5 | FAB-M5 | LP | 58 | 87 | Hyperdiploid 47XY; t (9;11); +8 | CD33/117+; HLA-DR+ |
| Pt #6 | FAB-M5 | LP | 103 | 83 | Pseudodiploid 46XX; t (9;11); Ras+; FLT3+ | CD13/14/15/33/38/64+; MPO+ |
| Pt #7 | FAB-M1 | PB | 55 | 90 | Hyperdiploid 47XX; +13 | CD13/15/33/34/38/117+; HLA-DR+; MPO+ |
| Pt #8 | FAB-M1 | PB | 157 | 92 | Diploid 46XX; FLT3+ | CD13/33/34/38/64/117+; HLA-DR+; MPO+ |
| Pt #9 | FAB-M5 | PB | 34 | 98 | Hypodiploid 43–46XY; del 5q; del 7q; del17p; del12p | CD13/33+; HLA-DR+ |
| Pt #10 | N/D | LP | 48 | 68 | Pseudodiploid, 46XX, t(1;16) | CD13/33/34/117+; HLA-DR+ |
| U-937 | Monocytic | N/A | N/A | N/A | N/A | N/A |
| HL-60 | Promyelocytic | N/A | N/A | N/A | N/A | N/A |
| Evaluated for P3 | ||||||
| Pt #11 | FAB-M1 | LP | 38 | 97 | Diploid 46XX; FLT3+ | CD7/13/33/34/38/117+; HLA-DR+; MPO+ |
| Pt #12 | FAB-M5 | LP | 90 | 57 | Diploid 46XX | CD13/14/15/33/38/45/64+; MPO+ |
| Pt #13 | CML-CP | PB | 25 | 30 | Diploid 46XX; t (9;22) | N/D |
| Evaluated for Both Proteins | ||||||
| Pt #14 | FAB-M1 | LP | 373 | 97 | Diploid 46XY; FLT3+; b2a2 BCR-ABL | CD7/13/33/34/38/117+; HLA-DR+; MPO+ |
| Pt #15 | FAB-M2 | LP | 65 | 43 | N/D | CD13/33/64/38+ |
| Pt #16 | FAB-M7 | PB | 7 | 76 | Hyperdiploid 49XY; del (5); del (7) | CD34/41/117+, HLA-DR+ |
| Pt #17 | 2nd AML | LP | 40 | 73 | Pseudodiploid 46XX; del (5); +12; Ras+ | CD13/33/34/117+; HLA-DR+ |
| Pt #18 | CML-AP | LP | 305 | 13 | Diploid 46XY; t(9;22); b3a2 b2a2 BCR-ABL | CD7/13/33/34/38/117+; HLA-DR+; MPO+ |
FAB indicates French-American-British classification; LP, leukapheresis; PB, peripheral blood; del, deletion; CML-AP, accelerated phase CML; CML-CP, chronic phase CML; MPO, myeloperoxidase, N/D, not determined; and N/A, not applicable.
*
In leukapheresis samples, cell count and blast percent was determined prior to sample apheresis.